Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 137 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Withdrawal of Application for the EMA Marketing Authorisation of Infigratinib December 1, 2022 Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies February 22, 2024 A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone... February 5, 2025 Home Is Where the Heart Is November 8, 2019 Load more HOT NEWS Sparing the Hippocampus During PCI Better Preserves Cognitive Function in Patients... Keeping progress in oncology on the agenda: ESMO honours recipients of... How Writing Helped Me Cope During Cancer Υποτροπιάζων ή μεταστατικός καρκίνος κεφαλής και τραχήλου: Νέα δεδομένα αναμένεται ότι...
